Table 1 Incidence of medication-related osteonecrosis of the jaw (MRONJ) in antiresorptive drug users in Finland stratified by age, gender, type of antiresorptive drug, purpose of use, history of corticosteroid and history of vascular endothelial growth factors (VEGFs).
Low-dose recipients | High-dose recipients | |||
|---|---|---|---|---|
Without MRONJ n (%) | With MRONJ n (%) | Without MRONJ n (%) | With MRONJ n (%) | |
Age group | ||||
≤ 64 years | 3702 (8.90%) | 15 (10.71%) | 452 (15.37%) | 52 (17.81%) |
≥ 64 years | 37,889 (91.10%) | 125 (89.29%) | 2489 (84.63%) | 240 (82.19%) |
Gender ** | ||||
Male | 5394 (13.52%) | 37 (27.61%) | 987 (39.04%) | 150 (54.55%) |
Female | 34,490 (86.48%) | 97 (72.39%) | 1541 (60.96%) | 125 (45.45%) |
Antiresorptive drug | ||||
Bisphosphonates | 27,139 (65.25%) | 38 (27.14%) | 645 (21.93%) | 17 (5.82%) |
Denosumab | 7002 (16.84%) | 77 (55.00%) | 1847 (62.8%) | 238 (81.51%) |
Both | 7450 (17.91%) | 25 (17.86%) | 449 (15.27) | 37 (12.67%) |
Diagnosis codes | ||||
Osteoporosis | 41,590 (100%) | 110 (78.57%) | 547 (18.6%) | 24 (8.22%) |
Breast cancer | 937 (2.25%) | 19 (13.57%) | 767 (26.02%) | 122 (41.78%) |
Prostate cancer | 146 (0.35%) | 24 (17.14%) | 489 (16.63%) | 121 (41.44%) |
Multiple myeloma | - | - | 517 (17.58) | 16 (5.48%) |
History of corticosteroids | ||||
Yes | 479 (1.15%) | 30 (21.43%) | 579 (19.69%) | 115 (39.38%) |
No | 41,112 (98.85%) | 110 (78.57%) | 2362 (80.31%) | 177 (60.62%) |
History of VEGF inhibitors | ||||
Yes | 44 (0.11%) | < 5 (< 3.0%) * | 198 (6.73%) | 49 (16.78%) |
No | 41,547 (99.89%) | < 137 (< 97.0%) | 2743 (93.27%) | 243 (83.22%) |
